WASHINGTON — The House easily approved a sweeping biomedical bill Wednesday that would help drug and medical device companies win swifter government approval of their products, boost disease research and drug-abuse spending and revamp federal mental health programs.

The compromise, which envisions spending $6.3 billion over the next decade, was condemned by consumer groups and some Democrats as a present to drugmakers that promised only paltry spending increases for underfunded federal programs.

But their objections were overwhelmed by an alliance among Republicans, many Democrats and the White House for a 996-page measure that bore wins for both parties. The Senate’s expected final approval next week would mark an uncommon episode of cooperation between the GOP-run 114th Congress – which plans to adjourn next week – and President Obama in their dwindling days in office.

The vote was 392-26.

“We are on the cusp of something special, a once-in-a-generation opportunity to transform how we treat disease,” said Rep. Fred Upton, R-Mich., chairman of the House Energy and Commerce Committee and an author of the legislation.

Not everyone agreed.

Rep. Rose DeLauro, D-Conn., said that while the bill contained “noble goals that I share,” its relaxation of some standards for federal drug approvals was dangerous and “neglects the very people clinical trials are meant to help – that is the patients.”

No. 2 Senate Democratic leader Richard Durbin of Illinois said he was “totally underwhelmed” by the bill’s extra money, and said its cuts in a disease prevention fund created under Obama’s health care law to finance new medical research displayed “a warped sense of justice.”


Only subscribers are eligible to post comments. Please subscribe or login first for digital access. Here’s why.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.